Visitors can source product, find potential partners and assess the market at first hand
The most populous country in world and with one of the fastest developing economies, the Chinese pharmaceutical sector is also growing at a prodigious rate. The pharma market in China is projected to be the third largest in the world by next year and the second largest by 2020, while revenues continue to enjoy double-digit growth.
But although China has risen swiftly to become one of the biggest players in global pharma, there is still widespread uncertainty about how to exploit the opportunities that exist, and how to build successful business relationships.
CPhI China 2010, which takes place from 2 – 4 June in the Shanghai New International Expo Centre, will deliver the most comprehensive solution, offering the opportunity to make contact with more than 1,600 exhibitors showcasing everything from APIs to intermediates, excipients to fine chemicals.
China is one of the biggest marketplaces to source new pharma ingredients at competitive prices. For companies affected by the economic downturn, cost savings will be high on the list of priorities. China combines low production costs with huge production capacities.
The country is now the world’s biggest producer and exporter of APIs – more than 1,500 types can be sourced there – and CPhI China offers a chance to assess suppliers at first hand.
With a growth rate of around 30% a year, the Chinese pharma sector is maturing rapidly and there is a strong need and desire for international collaborations. The exhibition presents an opportunity to find the right partner and to maintain and build strategic partnerships in a professional and international environment.
Colocated with P-MEC (machinery & equipment), ICSE (contract services), and – for the first time – BioPh (biopharmaceuticals), visitors will find all their pharma needs met under one roof.